Real-world cost-effectiveness of etonogestrel implants compared to long-term and short term reversible contraceptive methods in France.


Journal

The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception
ISSN: 1473-0782
Titre abrégé: Eur J Contracept Reprod Health Care
Pays: England
ID NLM: 9712127

Informations de publication

Date de publication:
Aug 2021
Historique:
pubmed: 8 5 2021
medline: 28 10 2021
entrez: 7 5 2021
Statut: ppublish

Résumé

To estimate the cost-effectiveness (CE) of etonogestrel implants compared to other long-term and short-term reversible contraceptive methods available in France. A 6-year Markov model compared effectiveness between the implant and six other contraceptive methods in sexually active, not-pregnancy-seeking French females of reproductive age. Contraception efficacy, switch rates and outcomes were based on French current medical practice. Incremental CE ratios (ICERs) were calculated as incremental cost per unintended pregnancy (UP) avoided. Efficiency frontier was plotted to identify cost-effective methods. Uncertainty was explored through sensitivity analyses. The implant was on the efficiency frontier along with combined oral contraceptive pill (COC) and copper IUD. Implant avoids between 0.75% and 3.53% additional UP per person-year compared to copper IUD and second generation COC, respectively, with an ICER of €2,221 per UP avoided compared to copper IUD. For the 240,000 French women currently using the implant, up to 8,475 UPs and up to 1,992 abortions may be prevented annually. With more unintended pregnancies avoided and comparable costs to copper IUD, the implant is a cost-effective option among long-term and short-term reversible contraceptive methods.

Sections du résumé

BACKGROUND BACKGROUND
To estimate the cost-effectiveness (CE) of etonogestrel implants compared to other long-term and short-term reversible contraceptive methods available in France.
RESEARCH DESIGN AND METHODS METHODS
A 6-year Markov model compared effectiveness between the implant and six other contraceptive methods in sexually active, not-pregnancy-seeking French females of reproductive age. Contraception efficacy, switch rates and outcomes were based on French current medical practice. Incremental CE ratios (ICERs) were calculated as incremental cost per unintended pregnancy (UP) avoided. Efficiency frontier was plotted to identify cost-effective methods. Uncertainty was explored through sensitivity analyses.
RESULTS RESULTS
The implant was on the efficiency frontier along with combined oral contraceptive pill (COC) and copper IUD. Implant avoids between 0.75% and 3.53% additional UP per person-year compared to copper IUD and second generation COC, respectively, with an ICER of €2,221 per UP avoided compared to copper IUD. For the 240,000 French women currently using the implant, up to 8,475 UPs and up to 1,992 abortions may be prevented annually.
CONCLUSION CONCLUSIONS
With more unintended pregnancies avoided and comparable costs to copper IUD, the implant is a cost-effective option among long-term and short-term reversible contraceptive methods.

Identifiants

pubmed: 33960248
doi: 10.1080/13625187.2021.1900562
doi:

Substances chimiques

Contraceptive Agents, Female 0
Contraceptives, Oral 0
etonogestrel 304GTH6RNH
Levonorgestrel 5W7SIA7YZW
Desogestrel 81K9V7M3A3

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

303-311

Auteurs

Teddy Linet (T)

Service de Gynécologie Obstétrique, Centre Hospitalier Loire Vendée Océan, Challans, France.

Laurie Lévy-Bachelot (L)

Laboratoire MSD France, Puteaux, France.

Gaëlle Farge (G)

Laboratoire MSD France, Puteaux, France.

Simone Crespi (S)

Merck & Co., Inc, Kenilworth, NJ, USA.

Joe Z Yang (JZ)

Merck & Co., Inc, Kenilworth, NJ, USA.

Julien Robert (J)

Cemka, Bourg-la-Reine, France.

Cécile Fabron (C)

Cemka, Bourg-la-Reine, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH